The anti-tuberculosis regimen containing rifampicin has been shown to increase efavirenz clearance in subjects with a wildtype CYP2B6 allele but decreases the clearance in those homozygous for defective variant alleles26. This evidence concerns the gene CYP2B6 and tuberculosis.